Clinical Trials Sponsored by Leland Metheny

Total 2652 results

Zealand Pharma

Completed

A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector.

Healthy

Netherlands
Zealand Pharma

Completed

A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects

Hypoglycemia | Diabetes Mellitus, Type 1

Canada, United States, Austria, Germany
Zealand Pharma

Completed

A Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

Healthy

Germany
Region Zealand

Unknown

Internal Hernias After Gastric Bypass Can be Prevented Safely With Primary Closure of All Mesenteric Defects With Clips

Internal Hernias

Denmark
Ligand Pharmaceuticals

Completed

A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Ligand Pharmaceuticals

Completed

Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus (L6972-02)

Type 2 Diabetes Mellitus

United States
Ligand Pharmaceuticals

Completed

Compare CE-Budesonide Nasal Solution & Rhinocort Aqua in an EEC Study of AR

Seasonal Allergic Rhinitis

Canada
Ligand Pharmaceuticals

Completed

Compare Captisol-Enabled (CE) Budesonide + Azelastine Nasal Solution and Rhinocort Aqua + Astelin in an Environmental Exposure Chamber (EEC) Study of Allergic Rhinitis

Seasonal Allergic Rhinitis

Canada
Ligand Pharmaceuticals

Completed

A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension

Hypertension

United States
Ligand Pharmaceuticals

Completed

The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation (LACE)

Bone Loss

United Kingdom
Zealand Pharma

Completed

Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose

Inflammatory Bowel Disease

United States
National University of Ireland, Galway, Ireland
Health Research Board, Ireland

Recruiting

Comparison of Multi-Round and Real-Time Delphi Survey Methods

Consensus Development

Ireland
National University of Ireland, Galway, Ireland
Health Research Board, Ireland

Recruiting

Cognitive Remediation and Social Recovery in Early Psychosis (CReSt-R)

Psychosis

Ireland
Horizon Therapeutics Ireland DAC

Completed

Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy

Uncontrolled Gout

United States
National University of Ireland, Galway, Ireland
Health Research Board, Ireland

Completed

Supporting the Improvement and Management of Prescribing for Urinary Tract Infections (SIMPle) (SIMPle)

Uncomplicated Urinary Tract Infection

Ireland
National University of Ireland, Galway, Ireland

Not yet recruiting

EMERGE Mothers and Kids

Gestational Diabetes
National University of Ireland, Galway, Ireland

Recruiting

Cognitive Stimulation in Daily Activities for People Living With Early to Middle Stage Dementia (CS-ADL)

Dementia | Dementia, Mild | Dementia Moderate

Ireland
National University of Ireland, Galway, Ireland

Recruiting

The PIONEER-IV Study is Comparing Clinical Outcomes Between Angiography-derived Physiology Guidance to Usual Care in an All-comers PCI Population With Unrestrictive Use of the HT Supreme Sirolimus-eluting Stent (PIONEER-IV)

Coronary Artery Disease

Belgium, Netherlands, Ireland, United Kingdom, Spain
National University of Ireland, Galway, Ireland

Unknown

MySlainte: Testing the Effect of Involving Partners in a CVD Prevention Community Lifestyle Program

Chronic Kidney Diseases | Rheumatoid Arthritis | Cardiovascular Risk Factor | Partner, Domestic

Ireland
National University of Ireland, Galway, Ireland

Suspended

The Galway Sea Swimmers Study (GS3)

Cardiovascular Diseases | Hypertension

Ireland
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)

Juvenile Idiopathic Arthritis (JIA)

United States
National University of Ireland, Galway, Ireland

Unknown

Compassion-Focused Therapy for People With Severe Obesity. (CFT)

Severe Obesity
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)

Urea Cycle Disorders

United States, Canada
National University of Ireland, Galway, Ireland

Unknown

Comfort and Tolerance of Surface Neuro Muscular Electrical Stimulation in Parkinson's Disease.

Parkinson's Disease

Ireland
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis (CAPRA-2)

Rheumatoid Arthritis

United States, Germany, Hungary, Canada, Poland, United Kingdom
Horizon Pharma Ireland, Ltd., Dublin Ireland

Completed

Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216) (HZ-CA-304)

Osteoarthritis | Rheumatoid Arthritis | Chronic Low Back Pain | Chronic Regional Pain Syndrome | Chronic Soft Tissue Pain

United States
Region Zealand

Recruiting

Botulinum Toxin for Chronic Neuropathic Pain

Chronic Pain | Neuralgia

Denmark
Zealand Pharma

Active, not recruiting

Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism

Congenital Hyperinsulinism

United States, United Kingdom, Germany, Israel
Zealand Pharma

Completed

The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome (EASE SBS 4)

Short Bowel Syndrome

Denmark
Zealand Pharma

Completed

Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS) (EASE SBS 1)

Short Bowel Syndrome

United States, Denmark, Belgium, Germany, France, United Kingdom, Canada, Netherlands, Poland
Zealand Pharma

Completed

Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

Congenital Hyperinsulinism

United States, United Kingdom, Israel, Germany
Zealand Pharma

Completed

A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM

Hypoglycemia | Diabetes Mellitus, Type 1

Canada
Zealand Pharma

Withdrawn

Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults

Glucose Metabolism Disorders | Hypoglycemia
Zealand Pharma

Completed

A Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

Healthy

Germany
Zealand Pharma

Completed

Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV Administration

Hypoglycemia

Germany
Zealand Pharma

Completed

Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Function

Renal Impairment

Hungary, Poland
Region Zealand

Completed

Reconstruction of the Anterior Cruciate Ligament(ACL-R) in the 30+-Year Old Assessed by Patient Reported Outcome Measures(PRO) Using the Nationwide Danish Knee Ligament Reconstruction Registry

Cruciate Ligament Rupture

Denmark
Zealand Pharma

Completed

Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction

Focus of Study is STEMI

Denmark
Zealand Pharma

Completed

ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon

Diabetes Mellitus Type 1

Germany
Demand Investigators

Unknown

Diastolic Heart Failure Management by Nifedipine (DEMAND)

Diastolic Heart Failure

Japan
Zealand Pharma

Completed

Multiple Ascending Doses of ZP4207 Administered to HV to Evaluate the Safety, Tolerability, PKs and PDs of ZP4207

Hypoglycemia

Germany
Ligand Pharmaceuticals

Completed

Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Ligand Pharmaceuticals

Completed

The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease

Early Stage Parkinson's Disease

United States
Ligand Pharmaceuticals

Completed

The Effects of Aplindore on the Treatment of Signs and Symptoms of Restless Legs Syndrome

Restless Legs Syndrome

United States
Ligand Pharmaceuticals

Completed

A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension

Hypertension

United States
Ligand Pharmaceuticals

Completed

Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL) (PEARL)

Osteoporosis

United States, Australia, Canada, Costa Rica, Germany, Russian Federation, France, Croatia, South Africa, Belgium, Japan, India, Spain, United Kingdom, Italy, Egypt, Turkey, Lithuania, Poland, Norway, Estonia, Finland, Denmark, Hong Kong and more
Ligand Pharmaceuticals

Withdrawn

Study of MB07811 in Subjects With Hypercholesterolemia

Hypercholesterolemia

United States
Ligand Pharmaceuticals

Completed

Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States, Hong Kong, Taiwan
Ligand Pharmaceuticals

Completed

Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss (CORAL)

Osteoporosis

United States
Zealand Pharma

Enrolling by invitation

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial (EASE SBS 3)

Short Bowel Syndrome

Germany, United States, Belgium, Denmark, France, United Kingdom, Netherlands, Poland

3

Subscribe